Revenue
2020
2021
Nicox SA (COX)
Price—Loading quote
Financial statements
| 2021 | 2020 | |
|---|---|---|
| Revenue | €7.2M | €12.9M |
| Research & development | €17.9M | €12.7M |
| Operating income | −€46.0M | −€6.8M |
| Operating margin | −636.11% | −52.37% |
| EBITDA | −€16.6M | −€5.0M |
| EBITDA margin | −229.35% | −38.87% |
| Net income | −€43.8M | −€18.1M |
| Net profit margin | −605.02% | −140.22% |
| Basic EPSper basic share | -€1.17 | -€0.54 |
| Diluted EPSper diluted share | -€1.17 | -€0.54 |
Owners
Reported shareholders and owner groups
3.46%of company shares
Ocumension TherapeuticsSource updated Jun 10, 2026
View holders
| Holder | Ownership |
|---|---|
| 3.46%Jun 10, 2026 | |
| 2.04%Jun 10, 2026 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Oct 21, 2026